TrialBMC neurology2022

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.

Patricia Pozo-Rosich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.